Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma: Molecular Therapy - Oncolytics
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy
Antibody therapy targeting CD19 for B-cell non-Hodgkin's lymphoma - Annals of Oncology
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy | Oncology
Brain Sciences | Free Full-Text | Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab | HTML
Rituximab in dermatology | Actas Dermo-Sifiliográficas
How the discovery of rituximab impacted the treatment of B-cell non-Ho | JBM
Rituximab (Rituxan) | American Journal of Neuroradiology
Rituximab - Wikipedia
Rituximab: Mechanism of Action - ScienceDirect
Current perspective on rituximab in rheumatic diseases | DDDT
Rituximab mechanisms of action; the three major independent mechanisms... | Download Scientific Diagram
Rituximab | Immunopaedia
Rituximab for the treatment of multiple sclerosis: a review | SpringerLink
Targeting CD20: Monoclonals of the future - ppt download
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab - ScienceDirect
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Main mechanisms of action of rituximab and ways to increase its... | Download Scientific Diagram
Use of rituximab in paediatric nephrology | Archives of Disease in Childhood
Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text
Figure 1 | Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives
Frontiers | Rituximab Therapy for Primary Sjögren's Syndrome | Pharmacology
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
